Intervacc is trading at €0.06, up 12.05%, after its November 3 announcement reported near-100% real-world protection from Strangvac.
- After 100,000 doses were sold in the EU and UK, only three confirmed infections were reported among horses completing primary vaccination.
- The company-specific announcement is the clearest explanation for the gain; supplied sector context describes biotechnology shares moving lower.
- No volume information was provided.